These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16082353)

  • 1. The zinc finger nuclease monopoly.
    Scott CT
    Nat Biotechnol; 2005 Aug; 23(8):915-8. PubMed ID: 16082353
    [No Abstract]   [Full Text] [Related]  

  • 2. A license to print money?
    Nat Biotechnol; 2006 Jun; 24(6):593. PubMed ID: 16763570
    [No Abstract]   [Full Text] [Related]  

  • 3. Kenyan dispute illuminates bioprospecting difficulties.
    Sheridan C
    Nat Biotechnol; 2004 Nov; 22(11):1337. PubMed ID: 15529141
    [No Abstract]   [Full Text] [Related]  

  • 4. Four rebuffs for Cabilly.
    Waltz E
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392001
    [No Abstract]   [Full Text] [Related]  

  • 5. India's IP snub.
    Jayaraman KS
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent Supreme Court decisions and licensing power.
    Giordano-Coltart J; Calkins CW
    Nat Biotechnol; 2008 Feb; 26(2):183-5. PubMed ID: 18259170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australia experiments with 'experimental use' exemption.
    McBratney A; Nielsen K; McMillan F
    Nat Biotechnol; 2004 Aug; 22(8):1023-5. PubMed ID: 15286651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A
    Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
    [No Abstract]   [Full Text] [Related]  

  • 9. Protecting methods for treatment related to regenerative medicine and gene therapy in Japan.
    Kaneshiro K; Masuda S; Tanaka Y; Tamai K
    Nat Biotechnol; 2004 Mar; 22(3):343-5. PubMed ID: 14990960
    [No Abstract]   [Full Text] [Related]  

  • 10. Licensing research tool patents.
    Flattmann GJ; Kaplan JM
    Nat Biotechnol; 2002 Sep; 20(9):945-7. PubMed ID: 12205511
    [No Abstract]   [Full Text] [Related]  

  • 11. Alnylam dealt blow.
    Mullard A
    Nat Biotechnol; 2009 Mar; 27(3):213. PubMed ID: 19270653
    [No Abstract]   [Full Text] [Related]  

  • 12. Burning bridges.
    Nat Biotechnol; 2007 Jan; 25(1):2. PubMed ID: 17211373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trendspotting: a shift in intellectual property focus.
    Anderegg MH; Thayer JM; Williams KM
    Nat Biotechnol; 2006 Jun; 24(6):609-11. PubMed ID: 16862639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myriad stands alone.
    Sherkow JS; Scott C
    Nat Biotechnol; 2014 Jul; 32(7):620. PubMed ID: 25004225
    [No Abstract]   [Full Text] [Related]  

  • 15. Creative Commons ponders share options.
    Gould P
    Nature; 2004 Nov; 432(7014):137. PubMed ID: 15538333
    [No Abstract]   [Full Text] [Related]  

  • 16. Intellectual property: patents and transfer agreements preceding clinical trials and commercialization.
    Ross TP
    Retina; 2005 Dec; 25(8 Suppl):S91-S94. PubMed ID: 16374360
    [No Abstract]   [Full Text] [Related]  

  • 17. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent patent applications in gene therapy.
    Nat Biotechnol; 2006 May; 24(5):520. PubMed ID: 16680131
    [No Abstract]   [Full Text] [Related]  

  • 19. Restrictive covenants.
    Jerrold L
    Am J Orthod Dentofacial Orthop; 1994 Mar; 105(3):313-4. PubMed ID: 8135220
    [No Abstract]   [Full Text] [Related]  

  • 20. Excerpts from "Let's Get Back to the Competitive Market System." Originally published in November-December 1973.
    Grayson CJ
    Harv Bus Rev; 1990; 68(6):84. PubMed ID: 10107965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.